Abstract
Long-term control of hilar cholangiocarcinoma (CCA) and extrahepatic cholangiocarcinoma (CCA) in general can only be obtained with complete surgical removal of all neoplastic tissue in toto either via surgical resection or transplantation [1]. Most investigators have demonstrated that complete surgical resection with negative margins (R0 resection) is the most important determinant of survival in hilar CCA [2, 3]. However, only a minority of patients are able to receive an oncologic resection [4]. Moreover, even after complete resection with negative margins the overall survival of patients with hilar CCA has been reported to range from 30 % to 52 % [5]. Murakami et al. [6] suggested that patients with UICC stage II and III CCAs to receive adjuvant therapy due to the high recurrence rate compare to Stage I tumors. The most common site of first recurrence after oncologic resection of hilar CCA is locoregional which often leads to potentially fatal complications such as biliary obstruction, sepsis and liver failure [4, 7, 8]. Only approximately 10-15 % of patients develop distant metastases before locoregional recurrence [7].
| Original language | English (US) |
|---|---|
| Title of host publication | Hilar Cholangiocarcinoma |
| Publisher | Springer Netherlands |
| Pages | 281-289 |
| Number of pages | 9 |
| ISBN (Electronic) | 9789400764736 |
| ISBN (Print) | 9400764723, 9789400764729 |
| DOIs | |
| State | Published - Jan 1 2013 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Neoadjuvant/adjuvant therapy for liver resection and transplantation. / Goh, B. K P; Rosen, C. B.
Hilar Cholangiocarcinoma. Springer Netherlands, 2013. p. 281-289.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Neoadjuvant/adjuvant therapy for liver resection and transplantation
AU - Goh, B. K P
AU - Rosen, C. B.
PY - 2013/1/1
Y1 - 2013/1/1
N2 - Long-term control of hilar cholangiocarcinoma (CCA) and extrahepatic cholangiocarcinoma (CCA) in general can only be obtained with complete surgical removal of all neoplastic tissue in toto either via surgical resection or transplantation [1]. Most investigators have demonstrated that complete surgical resection with negative margins (R0 resection) is the most important determinant of survival in hilar CCA [2, 3]. However, only a minority of patients are able to receive an oncologic resection [4]. Moreover, even after complete resection with negative margins the overall survival of patients with hilar CCA has been reported to range from 30 % to 52 % [5]. Murakami et al. [6] suggested that patients with UICC stage II and III CCAs to receive adjuvant therapy due to the high recurrence rate compare to Stage I tumors. The most common site of first recurrence after oncologic resection of hilar CCA is locoregional which often leads to potentially fatal complications such as biliary obstruction, sepsis and liver failure [4, 7, 8]. Only approximately 10-15 % of patients develop distant metastases before locoregional recurrence [7].
AB - Long-term control of hilar cholangiocarcinoma (CCA) and extrahepatic cholangiocarcinoma (CCA) in general can only be obtained with complete surgical removal of all neoplastic tissue in toto either via surgical resection or transplantation [1]. Most investigators have demonstrated that complete surgical resection with negative margins (R0 resection) is the most important determinant of survival in hilar CCA [2, 3]. However, only a minority of patients are able to receive an oncologic resection [4]. Moreover, even after complete resection with negative margins the overall survival of patients with hilar CCA has been reported to range from 30 % to 52 % [5]. Murakami et al. [6] suggested that patients with UICC stage II and III CCAs to receive adjuvant therapy due to the high recurrence rate compare to Stage I tumors. The most common site of first recurrence after oncologic resection of hilar CCA is locoregional which often leads to potentially fatal complications such as biliary obstruction, sepsis and liver failure [4, 7, 8]. Only approximately 10-15 % of patients develop distant metastases before locoregional recurrence [7].
UR - http://www.scopus.com/inward/record.url?scp=84931360760&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84931360760&partnerID=8YFLogxK
U2 - 10.1007/978-94-007-6473-6_26
DO - 10.1007/978-94-007-6473-6_26
M3 - Chapter
AN - SCOPUS:84931360760
SN - 9400764723
SN - 9789400764729
SP - 281
EP - 289
BT - Hilar Cholangiocarcinoma
PB - Springer Netherlands
ER -